DYSTROGEN
THERAPEUTICS

Title: Dystrogen Therapeutics Received a Positive Opinion from the Institutional Board Review/Ethics Committee to perform a first-in-human trial of the company's innovative personalized chimeric cell therapy for patients suffering from Duchenne muscular dystrophy.

Chicago April 26th, 2019

Dystrogen Therapeutics Inc. is pleased to announce that the IRB/ethics committee approved the first-in-human study with the company's innovative chimeric cell therapy to be used in patients suffering from Duchenne muscular dystrophy. Ten boys, ages 5 – 15 years old, are planned to be recruited. The patients will have the new drug administered systemically via intraosseous delivery. Each patient will be under observation for 12 months.

The primary aim of the study is to verify the safety and tolerability of the investigated medicinal product. Improvements in functional outcomes will be recorded as secondary endpoints. Dystrogen Therapeutics S.A. will serve as the study's sponsor.

Patient recruitment is planned for the second half of 2019 and the first data readouts are expected in the first half of 2020. "We believe, that treatment of the first patient in this study will be a very important scientific and medical milestone. Our efforts demonstrate that we can create chimeric cell-based therapeutics as new class of personalized medicines for patients with rare genetic diseases." – said Prof. Maria Siemionow MD, PhD, the technology inventor.

"This trial will be an important milestone in managing patients with Duchenne muscular dystrophy, a disease that is currently incurable and life-threatening. Additionally, the chimeric cell approach has the potential to exclude the need for immunosuppression, commonly associated with cell-based therapies, thus eliminating the toxic side-effects to the human organism." said Dr. Kris Siemionow MD PhD – Dystrogen's Chief Executive Officer.

Dystrogen Therapeutics is a clinical-stage life sciences company committed to developing personalized therapies for rare genetic diseases. The company has two unique technology platforms: Chimeric Cell-based Therapy Platform and Gene Therapy Platform (based on RNA interference technology).

More information: info@dystrogen.com